PSY14 A LITERATURE REVIEW TO IDENTIFY, CRITIQUE AND SELECT THE MOST SUITABLE ECONOMIC MODEL FOR USE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) UK HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS

Abstract

Conduct a literature search to identify the most suitable economic model for use in Systemic Lupus Erythematosus (SLE) to support National Institute for Health and Care Excellence (NICE) Health Technology Appraisal (HTA) submissions for new biological medicines. A systematic literature review was undertaken using OVID software to search the Medline and Embase databases. Hand searches of NICE, NHS EED, The Cochrane Collaboration and conference literature were also conducted. The results were analysed over two rounds to pre-determined Patient, Intervention, Comparator, Outcomes, Study (PICOS) inclusion/exclusion criteria. Data extraction was performed on the identified full articles using an adapted Consolidated Health Economic Evaluation Reporting Standards (CHEERS) check-list. The findings were critiqued to identify the most suitable economic model to use in the SLE disease area and a graphical representation of an adapted model was produced. The literature search identified 1,795 articles. Round one: abstract data analysis identified 8 abstracts as “included”, 6 abstracts as “unsure” and 1,781 as “excluded.” Round two: full article data analysis identified 8 full articles as “included” and 6 full articles as “excluded.” The 8 articles entered the CHEERS check-list data extraction round. The patient level microsimulation model presented in the NICE TA397 submission met the highest number of criteria. The research identified a patient level microsimulation model as the most suitable economic model to support a NICE HTA submission. Additional model benefits may be gained by incorporating multiple organ damage, adding comparative data of other biologic treatments from the BILAG registry, including a maximum treatment duration for the drug regime being assessed in line with current clinical practice and accounting for SLE flares. Including these into an economic model may improve Incremental Cost-Effectiveness Ratio (ICER) accuracy, minimise uncertainty in the results and ultimately aid to reduce the burden to patients with SLE.